Transitioning to Pegylated Interferon for the Treatment of Cutaneous T-Cell Lymphoma: Meeting the Challenge of Therapy Discontinuation and a Proposed Algorithm
Table 2
Patient demographics, clinical features, and outcomes.
Patient
Age at diagnosis
Pathology diagnosis
Stage
IFN dose/week (MU)
TTNT-IFN (months)†
PEG-IFN start dose/week (ug)
Concurrent therapies‡
mSWAT (baseline)
SkinDex-29 (baseline)
PEG-IFN current dose
Adverse effects
Next line of treatment
TTNT–PEG-IFN (days) §
Time on PEG-IFN (months)¶
mSWAT
SkinDex-29
Outcome
OS from diagnosis (years)
1
50
SS
IVB
6
8
90
ECP
84
72
—
Moga
24
0.8
80
62
Alive
1.2
2
66
SS
IVB
6
7
90
ECP, retinoids
90
116
—
Moga
37
1.2
90
116
Alive
1.0
3
60
MF, LCT
IIB
6
38
90
UVB, carmustine
3
59
70
Decreased mood
—
—
6
20
61
Alive
9.6
4
69
MF (folliculotropic)
IIB
4.5
19
90
Acitretin, imiquimod, TCS
12
55
90
—
—
5
11
35
Alive
2.4
5
73
MF
IIB
9
21
90
UVB
80
52
—
Romi
128
4.3
60
76
Alive
13.6
6
67
MF, LCT
IIB
6
8
90
Isotretinoin
53.5
71
90
TSEB¶¶
—
5
26
Alive
5.4
7
86
MF, LCT
IIB
9
5
90
—
34
36
45
Grade 1 anemia
—
—
6
23
34
Alive
22.7
8
71
MF
IIIA
6
57
45
ECP, alitretinoin
NR
NR
45
—
—
5
27
Alive
7.9
†TTNT between interferon and pegylated interferon, ‡concurrent therapies during both IFN and PEG-IFN, § TTNT between pegylated interferon and the next line of treatment, if applicable, ¶ as of time of the publication, ¶¶ the patient was initiated on TSEB while remaining on PEG-IFN, initiated after 36 days on PEG-IFN. OS, overall survival; Moga, mogamulizumab; Romi, romidepsin; TSEB, total skin electron beam therapy; NR, not recorded